We’ve recently updated our valuation analysis.

Seegene Valuation

Is A096530 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A096530?

Other financial metrics that can be useful for relative valuation.

A096530 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA2.1x
PEG Ratio-0.1x

Price to Earnings Ratio vs Peers

How does A096530's PE Ratio compare to its peers?

The above table shows the PE ratio for A096530 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average18.5x
A064550 Bioneer
30.3x64.2%₩702.0b
A144510 GC Cell
13.6xn/a₩703.5b
A214450 PharmaResearch
16.3x16.9%₩757.2b
A006280 Green Cross
13.7x3.3%₩1.5t
A096530 Seegene
3.9x-34.5%₩1.3t

Price-To-Earnings vs Peers: A096530 is good value based on its Price-To-Earnings Ratio (3.9x) compared to the peer average (18.5x).


Price to Earnings Ratio vs Industry

How does A096530's PE Ratio compare vs other companies in the KR Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.0%
n/an/an/a

Price-To-Earnings vs Industry: A096530 is good value based on its Price-To-Earnings Ratio (3.9x) compared to the KR Biotechs industry average (24.5x)


Price to Earnings Ratio vs Fair Ratio

What is A096530's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A096530 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio3.9x
Fair PE Ratio10.1x

Price-To-Earnings vs Fair Ratio: A096530 is good value based on its Price-To-Earnings Ratio (3.9x) compared to the estimated Fair Price-To-Earnings Ratio (10.1x).


Share Price vs Fair Value

What is the Fair Price of A096530 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A096530 (₩27000) is trading above our estimate of fair value (₩17050.52)

Significantly Below Fair Value: A096530 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A096530 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩27,000.00
₩36,000.00
+33.3%
6.0%₩39,000.00₩34,000.00n/a3
Jan ’24₩27,200.00
₩36,000.00
+32.4%
6.0%₩39,000.00₩34,000.00n/a3
Dec ’23₩29,750.00
₩36,000.00
+21.0%
6.0%₩39,000.00₩34,000.00n/a3
Nov ’23₩29,050.00
₩42,200.00
+45.3%
4.6%₩44,100.00₩39,500.00n/a3
Oct ’23₩26,800.00
₩42,200.00
+57.5%
4.6%₩44,100.00₩39,500.00n/a3
Sep ’23₩30,750.00
₩42,200.00
+37.2%
4.6%₩44,100.00₩39,500.00n/a3
Aug ’23₩39,100.00
₩55,666.67
+42.4%
3.7%₩58,000.00₩53,000.00n/a3
Jul ’23₩33,900.00
₩55,666.67
+64.2%
3.7%₩58,000.00₩53,000.00n/a3
Jun ’23₩44,450.00
₩55,666.67
+25.2%
3.7%₩58,000.00₩53,000.00n/a3
May ’23₩40,550.00
₩81,500.00
+101.0%
4.3%₩85,000.00₩78,000.00n/a2
Apr ’23₩50,100.00
₩81,500.00
+62.7%
4.3%₩85,000.00₩78,000.00n/a2
Mar ’23₩51,300.00
₩81,500.00
+58.9%
4.3%₩85,000.00₩78,000.00n/a2
Feb ’23₩54,400.00
₩81,500.00
+49.8%
4.3%₩85,000.00₩78,000.00n/a2
Jan ’23₩61,000.00
₩79,000.00
+29.5%
1.3%₩80,000.00₩78,000.00₩27,200.002
Dec ’22₩69,500.00
₩79,000.00
+13.7%
1.3%₩80,000.00₩78,000.00₩29,750.002
Nov ’22₩55,100.00
₩84,500.00
+53.4%
5.3%₩89,000.00₩80,000.00₩29,050.002
Oct ’22₩58,600.00
₩84,500.00
+44.2%
5.3%₩89,000.00₩80,000.00₩26,800.002
Sep ’22₩66,900.00
₩112,000.00
+67.4%
20.5%₩135,000.00₩89,000.00₩30,750.002
Aug ’22₩70,000.00
₩116,750.00
+66.8%
15.6%₩135,000.00₩98,500.00₩39,100.002
Jul ’22₩85,500.00
₩116,750.00
+36.5%
15.6%₩135,000.00₩98,500.00₩33,900.002
Jun ’22₩68,300.00
₩153,375.00
+124.6%
27.8%₩215,000.00₩98,500.00₩44,450.004
May ’22₩93,600.00
₩145,800.00
+55.8%
28.5%₩215,000.00₩94,000.00₩40,550.005
Apr ’22₩67,200.00
₩145,900.00
+117.1%
28.4%₩215,000.00₩94,000.00₩50,100.005
Mar ’22₩62,250.00
₩145,900.00
+134.4%
28.4%₩215,000.00₩94,000.00₩51,300.005
Feb ’22₩89,850.00
₩165,280.00
+84.0%
17.8%₩215,000.00₩133,500.00₩54,400.005
Jan ’22₩96,500.00
₩165,280.00
+71.3%
17.8%₩215,000.00₩133,500.00₩61,000.005

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies